TeleHealth Model to Address Vaccine Hesitancy & Increase Vaccine Completion Among Communities in Southeastern Louisiana

Launched by XAVIER UNIVERSITY OF LOUISIANA. · Dec 27, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how a telehealth program can help people in Southeastern Louisiana feel more comfortable getting vaccinated, especially against COVID-19 and the flu. The study will last around 2 to 2.5 years and will involve participants receiving education about health and vaccinations. Some individuals will focus only on general wellness topics like nutrition and managing diabetes or high blood pressure, while others will also learn about the importance of vaccines. The trial is specifically seeking adults aged 18 to 55 who work in high-risk jobs, such as healthcare and food service, and who may not be fully vaccinated yet.

Participants will join individual and group sessions to discuss these topics and receive support through telehealth, which means you'll be able to connect with healthcare professionals through your phone, tablet, or computer. To be eligible, you should not have completed your COVID-19 vaccine series or boosters and must be able to speak English. This trial aims to make vaccines more accessible and encourage completion among communities that often face barriers to healthcare. If you have any allergies to vaccines or certain health conditions, you may not qualify for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Incomplete vaccination defined as 1a. Incomplete COVID-19 vaccine series 1b. Incomplete COVID-19 booster or annual COVID-19 vaccine 1c. Incomplete annual influenza
• • 2. Adults aged 18 years to 65 years of age
• • 3. Able to speak English
• • 4. Currently employed or seeking training in target industries such as: healthcare, education, beauty, hospitality, food (culinary) and industrial plant workers.
• • 5. Able to use Telehealth technology via tablet, cell phone, or computer
• Exclusion Criteria:
• • 1. Individuals who have completed the annual COVID-19 vaccine update.
• • 2. Individuals with documented allergy or reaction to COVID-19 or influenza vaccine
• • 3. Individuals who are unable to give informed consent.
• • 4. Individuals with diagnosis of immunosuppressive conditions such as cancer, primary immunodeficiency, or organ transplant recipients
• • 5. Individuals diagnosed with congestive heart failure
• • 6. Individuals diagnosed with any cardiac arrhythmia